Expression status of folate receptor α is significantly correlated with prognosis in non-small-cell lung cancers

Annals of Surgical Oncology

Volumn 15, Issue 3, 2008, Pages 889-899

  Iwakiri, Shotaro ^a   Sonobe, Makoto ^a   Nagai, Shinjiro ^a   Hirata, Toshiki ^a   Wada, Hiromi ^a   Miyahara, Ryo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Epidermal growth factor receptor (EGFR); Folate receptor (FOLR1); Non small cell lung cancer (NSCLC); Prognosis; Real time quantitative RT PCR; Reduced folate carrier (RFC1)

Indexed keywords

FOLATE RECEPTOR; FOLATE RECEPTOR ALPHA; PROTEIN P53; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; WILD TYPE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 39149083739     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9755-3     Document Type: Article

References (47)

1. Pearson FG. Non-small cell lung cancer: role of surgery for stages I-III. Chest 1999;116:500S-503S
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7
3. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004;56:1099-109
4. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr 2000;130:129-32
5. Ma DW, Finnell RH, Davidson LA, et al. Folate transport gene inactivation in mice increases sensitivity to colon carcinogenesis. Cancer Res 2005;65:887-97
6. Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates. Semin Oncol 1999;26:11-23
7. Spiegelstein O, Eudy JD, Finnell RH. Identification of two putative novel folate receptor genes in humans and mouse. Gene 2000;258:117-25
8. Matherly LH. Molecular and cellular biology of the human reduced folate carrier. Prog Nucleic Acid Res Mol Biol 2001;67:131-62
9. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 1971;186:20-36
10. Kamen BA, Wang MT, Streckfuss AJ, et al. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988;263:13602-9
11. Anderson RG, Kamen BA, Rothberg KG, et al. Potocytosis: sequestration and transport of small molecules by caveolae. Science 1992;255:410-1
12. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem Pharmacol 1992;44:1898-901
13. Brigle KE, Spinella MJ, Westin EH, et al. Increased expression and characterization of two distinct folate binding proteins in murine erythroleukemia cells. Biochem Pharmacol 1994;47:337-45
14. Zhao R, Russell RG, Wang Y, et al. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 2001;276:10224-8
15. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002;367:629-40
16. Prasad PD, Ramamoorthy S, Leibach FH, et al. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995;206:681-7
17. Chiao JH, Roy K, Tolner B, et al. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 1997;272:11165-70
18. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401
19. Weitman SD, Weinberg AG, Coney LR, et al. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:6708-11
20. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43
21. Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121:225-33
22. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999;8:775-82
23. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-67
24. Campbell IG, Jones TA, Foulkes WD, et al. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-38
25. Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8
26. Franklin WA, Waintrub M, Edwards D, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994;8:20-36
27. Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998:15:587-627
28. Gruner BA, Weitman SD. The folate receptor as a potential therapeutic anticancer target. Invest New Drugs 1998;16:205-19
29. Leamon CP, Low PS. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov Today 2001;6:44-51
30. Theti DS, Bavetsias V, Skelton LA, et al. Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res 2003;63:3612-8
31. Theti DS, Jackman AL. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004;10:1080-9
32. Tanaka F, Otake Y, Nakagawa T, et al. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res 2000;60:3072-80
33. Sonobe M, Manabe T, Wada H, et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 2005;93:355-63
34. Orita M, Iwahana H, Kanazawa H, et al. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766-70
35. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-6
36. Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003;9:6012-9
37. Levy AS, Sather HN, Steinherz PG, et al. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study. J Pediatr Hematol Oncol 2003;25:688-95
38. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-9
39. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5
40. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes. Correlates of molecular-structure and biological activity. Mol Pharmacol 1995;48:459-71
41. Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005;10:363-8
42. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23
43. Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95
44. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9
45. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46
46. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73
47. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63